RxDoctor Payments Data

Srinivas Kolipaka, MD

Psychiatry · Canton, GANPI 1831381433

Payments from drug & device makers

$1,487in general payments, 2019–2025

Across 83 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$319
  • AbbVie$308
  • Teva Pharmaceuticals USA, Inc.$222
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$214
  • Otsuka America Pharmaceutical, Inc.$98
  • Johnson & Johnson$89
  • plus $237 from 7 others

What the payments were for

  • Food & beverage$1,487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,487 in reported general payments places this provider in the 70th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$22,086
Medicare patients
82
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate69$222,536
Invega TrinzaPaliperidone Palmitate18$136,321
AustedoDeutetrabenazine14$129,214
Austedo XrDeutetrabenazine13$111,791
VraylarCariprazine Hcl58$83,993
Abilify MaintenaAripiprazole28$80,050
ClozarilClozapine13$12,377
Aripiprazole133$8,638
Buspirone Hcl345$4,274
Clozapine93$4,151
Quetiapine Fumarate200$3,243
Paliperidone ErPaliperidone28$3,029
Olanzapine115$2,814
Ziprasidone Hcl56$2,609
Oxcarbazepine64$2,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$89$358,85787 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Loxapine$222$241,78745 claims
AbbVieVraylar$308$83,99358 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$98$80,05028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →